Literature DB >> 23720744

Noncanonical role of the PDZ4 domain of the adaptor protein PDZK1 in the regulation of the hepatic high density lipoprotein receptor scavenger receptor class B, type I (SR-BI).

Kosuke Tsukamoto1, Thomas E Wales, Kathleen Daniels, Rinku Pal, Ren Sheng, Wonhwa Cho, Walter Stafford, John R Engen, Monty Krieger, Olivier Kocher.   

Abstract

The four PDZ (PDZ1 to PDZ4) domain-containing adaptor protein PDZK1 controls the expression, localization, and function of the HDL receptor scavenger receptor class B, type I (SR-BI), in hepatocytes in vivo. This control depends on both the PDZ4 domain and the binding of SR-BI's cytoplasmic C terminus to the canonical peptide-binding sites of either the PDZ1 or PDZ3 domain (no binding to PDZ2 or PDZ4). Using transgenic mice expressing in the liver domain deletion (ΔPDZ2 or ΔPDZ3), domain replacement (PDZ2→1), or target peptide binding-negative (PDZ4(G389P)) mutants of PDZK1, we found that neither PDZ2 nor PDZ3 nor the canonical target peptide binding activity of PDZ4 were necessary for hepatic SR-BI regulatory activity. Immunohistochemical studies established that the localization of PDZK1 on hepatocyte cell surface membranes in vivo is dependent on its PDZ4 domain and the presence of SR-BI. Analytical ultracentrifugation and hydrogen deuterium exchange mass spectrometry suggested that the requirement of PDZ4 for localization and SR-BI regulation is not due to PDZ4-mediated oligomerization or induction of conformational changes in the PDZ123 portion of PDZK1. However, surface plasmon resonance analysis showed that PDZ4, but not the other PDZ domains, can bind vesicles that mimic the plasma membrane. Thus, PDZ4 may potentiate PDZK1's regulation of SR-BI by promoting its lipid-mediated attachment to the cytoplasmic membrane. Our results show that not all of the PDZ domains of a multi-PDZ domain-containing adaptor protein are required for its biological activities and that both canonical target peptide binding and noncanonical (peptide binding-independent) capacities of PDZ domains may be employed by a single such adaptor for optimal in vivo activity.

Entities:  

Keywords:  Cholesterol Metabolism; High Density Lipoprotein (HDL); Protein-Protein Interactions; Receptors; Transgenic Mice

Mesh:

Substances:

Year:  2013        PMID: 23720744      PMCID: PMC3707687          DOI: 10.1074/jbc.M113.460170

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Analysis of reversibly interacting macromolecular systems by time derivative sedimentation velocity.

Authors:  W F Stafford
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

Review 2.  Assembly of cell regulatory systems through protein interaction domains.

Authors:  Tony Pawson; Piers Nash
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

3.  PDZ domain binding selectivity is optimized across the mouse proteome.

Authors:  Michael A Stiffler; Jiunn R Chen; Viara P Grantcharova; Ying Lei; Daniel Fuchs; John E Allen; Lioudmila A Zaslavskaia; Gavin MacBeath
Journal:  Science       Date:  2007-07-20       Impact factor: 47.728

4.  Identification of a PDZ-domain-containing protein that interacts with the scavenger receptor class B type I.

Authors:  M Ikemoto; H Arai; D Feng; K Tanaka; J Aoki; N Dohmae; K Takio; H Adachi; M Tsujimoto; K Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

5.  Accessory protein facilitated CFTR-CFTR interaction, a molecular mechanism to potentiate the chloride channel activity.

Authors:  S Wang; H Yue; R B Derin; W B Guggino; M Li
Journal:  Cell       Date:  2000-09-29       Impact factor: 41.582

6.  Differential roles of ionic, aliphatic, and aromatic residues in membrane-protein interactions: a surface plasmon resonance study on phospholipases A2.

Authors:  R V Stahelin; W Cho
Journal:  Biochemistry       Date:  2001-04-17       Impact factor: 3.162

7.  Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice.

Authors:  Anne Braun; Bernardo L Trigatti; Mark J Post; Kaori Sato; Michael Simons; Jay M Edelberg; Robert D Rosenberg; Mark Schrenzel; Monty Krieger
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

Review 8.  The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues.

Authors:  Attilio Rigotti; Helena E Miettinen; Monty Krieger
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

9.  Targeted disruption of the PDZK1 gene by homologous recombination.

Authors:  Olivier Kocher; Rinku Pal; Mark Roberts; Christine Cirovic; Annalyn Gilchrist
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

10.  Crystal structure of GRIP1 PDZ6-peptide complex reveals the structural basis for class II PDZ target recognition and PDZ domain-mediated multimerization.

Authors:  Young Jun Im; Seong Ho Park; Seong-Hwan Rho; Jun Hyuck Lee; Gil Bu Kang; Morgan Sheng; Eunjoon Kim; Soo Hyun Eom
Journal:  J Biol Chem       Date:  2002-12-18       Impact factor: 5.157

View more
  10 in total

Review 1.  Scavenger receptor class B type I (SR-BI): a versatile receptor with multiple functions and actions.

Authors:  Wen-Jun Shen; Jie Hu; Zhigang Hu; Fredric B Kraemer; Salman Azhar
Journal:  Metabolism       Date:  2014-03-21       Impact factor: 8.694

2.  NHERF2/NHERF3 protein heterodimerization and macrocomplex formation are required for the inhibition of NHE3 activity by carbachol.

Authors:  Jianbo Yang; Varsha Singh; Tian-E Chen; Rafiquel Sarker; Lishou Xiong; Boyoung Cha; Shi Jin; Xuhang Li; C Ming Tse; Nicholas C Zachos; Mark Donowitz
Journal:  J Biol Chem       Date:  2014-05-27       Impact factor: 5.157

Review 3.  HDL and Scavenger Receptor Class B Type I (SRBI).

Authors:  Hong Yu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 4.  Scavenger receptor B type 1: expression, molecular regulation, and cholesterol transport function.

Authors:  Wen-Jun Shen; Shailendra Asthana; Fredric B Kraemer; Salman Azhar
Journal:  J Lipid Res       Date:  2018-05-02       Impact factor: 5.922

5.  Carboxy-terminal deletion of the HDL receptor reduces receptor levels in liver and steroidogenic tissues, induces hypercholesterolemia, and causes fatal heart disease.

Authors:  Rinku Pal; Qingen Ke; German A Pihan; Ayce Yesilaltay; Marsha L Penman; Li Wang; Chandramohan Chitraju; Peter M Kang; Monty Krieger; Olivier Kocher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-30       Impact factor: 4.733

Review 6.  Applications of hydrogen/deuterium exchange MS from 2012 to 2014.

Authors:  Gregory F Pirrone; Roxana E Iacob; John R Engen
Journal:  Anal Chem       Date:  2014-11-14       Impact factor: 6.986

7.  Compound heterozygous variants in the multiple PDZ domain protein (MPDZ) cause a case of mild non-progressive communicating hydrocephalus.

Authors:  Nesreen K Al-Jezawi; Aisha M Al-Shamsi; Jehan Suleiman; Salma Ben-Salem; Anne John; Ranjit Vijayan; Bassam R Ali; Lihadh Al-Gazali
Journal:  BMC Med Genet       Date:  2018-03-02       Impact factor: 2.103

8.  HBV Infection-Related PDZK1 Plays an Oncogenic Role by Regulating the PI3K-Akt Pathway and Fatty Acid Metabolism and Enhances Immunosuppression.

Authors:  Xin Chen; Xiaodong Wang; Feng Zhu; Chao Qian; Fanggui Xu; Xin Huang; Wenjie Zhang; Beicheng Sun
Journal:  J Immunol Res       Date:  2022-08-23       Impact factor: 4.493

9.  Challenges in using cultured primary rodent hepatocytes or cell lines to study hepatic HDL receptor SR-BI regulation by its cytoplasmic adaptor PDZK1.

Authors:  Kosuke Tsukamoto; Lorenna Buck; Walker Inman; Linda Griffith; Olivier Kocher; Monty Krieger
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

10.  Interleukin-37 contributes to the pathogenesis of gout by affecting PDZ domain-containing 1 protein through the nuclear factor-kappa B pathway.

Authors:  Wei Wan; Yeqing Shi; Lianmei Ji; Xiaofang Li; Xia Xu; Dongbao Zhao
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.